发明授权
EP1934227B1 2-HETEROARYL-PYRAZOLO-[4, 3-e]-1, 2, 4-TRIAZOLO-[1,5-c]-PYRIMIDINE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
有权
2- HETEROARYLPYRAZOLO并[4,3-E] -1,2,4-三唑并[1,5-C]嘧啶作为腺苷A2A受体的拮抗剂
- 专利标题: 2-HETEROARYL-PYRAZOLO-[4, 3-e]-1, 2, 4-TRIAZOLO-[1,5-c]-PYRIMIDINE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
- 专利标题(中): 2- HETEROARYLPYRAZOLO并[4,3-E] -1,2,4-三唑并[1,5-C]嘧啶作为腺苷A2A受体的拮抗剂
-
申请号: EP06803715.9申请日: 2006-09-15
-
公开(公告)号: EP1934227B1公开(公告)日: 2011-12-21
- 发明人: NEUSTADT, Bernard, R. , BOYLE, Craig, D. , CHACKALAMANNIL, Samuel , HARRIS, Joel, M. , LANKIN, Claire, M. , LIU, Hong , SHAH, Unmesh, G. , STAMFORD, Andrew, W.
- 申请人: Schering Corporation
- 申请人地址: 2000 Galloping Hill Road Kenilworth, NJ 07030 US
- 专利权人: Schering Corporation
- 当前专利权人: Schering Corporation
- 当前专利权人地址: 2000 Galloping Hill Road Kenilworth, NJ 07030 US
- 代理机构: Jaap, David Robert
- 优先权: US718502P 20050919
- 国际公布: WO2007035542 20070329
- 主分类号: C07D487/14
- IPC分类号: C07D487/14 ; A61K31/519 ; A61P25/00
摘要:
Compounds having the structural formula (I) or a pharmaceutically acceptable salt thereof, wherein R is R1-isoxazolyl, R1-oxadiazolyl, R1-dihydrofuranyl, R1-pyrazolyl, R1-imidazolyl, R1-pyrazinyl or R1-pyrimidinyl; R1 is 1 , 2 or 3 substituents selected from H, alkyl, alkoxy and halo; Z is optionally substituted-aryl, or optionally substituted-heteroaryl; are disclosed, as well as their use in the treatment of central nervous system diseases, in particular Parkinson's disease and Extra Pyramidal Syndrome, pharmaceutical compositions comprising them, and combinations with other agents.
公开/授权文献
信息查询